Investor Relations
NASDAQ: PNT
POINT has built a platform to accelerate the next-generation of radiopharmaceuticals with an industry-leading pipeline, in-house manufacturing capabilities, and redundant supply of rare medical isotopes. The management team brings decades of combined experience in radiopharmaceutical clinical development and manufacturing, including 40+ clinical trials, 12 drug approvals, and 8 GMP radiopharmaceutical facilities, and has leveraged prior relationships to assemble one of the industry’s most resilient radioisotope supply chains. The company’s 100%-owned, 80,000 sq ft facility has capacity to commercially supply both North America and Europe for large volume indications. POINT has two late-stage programs one of which is PNT2002, currently being evaluated in the Phase 3 SPLASH study targeting mCRPC, which could lay the cornerstones of the company’s radiopharmaceutical platform. POINT also has an exciting early-stage pipeline which includes a best-in-class FAP-α targeted radioligand PNT2004, a potential pan-cancer target.
Investor Presentations
Supplementary Presentations:
POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO
PNT2004 program’s phase 1 FRONTIER trial design to be presented. Abstract to be released at 5:00 PM ET, May 25th. Poster to be available starting at 9:00 AM ET, June 3rd.
POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
U.S. FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC in April 2023. Announces $10 million strategic investment in commercial-scale alpha-emitting isotope manufacturer, Ionetix Alpha Corp.
Events Calendar
2023 UPCOMING EVENTS
April 26: 2023 Bloom Burton & Co. Healthcare Investor Conference
- Format: Presentation and 1x1 Meetings
- Webcast link available here
May 15: Guggenheim Second Annual Healthcare Talks Radiopharmaceuticals Day
- Format: Fireside Chat and 1x1 Meetings
- Location: Monday, May 15, 2023
June 1: Annual General Meeting
2023 PAST EVENTS
February 7: Guggenheim 5th Annual Oncology Conference
- Format: Fireside Chat and 1x1 Meetings
- Webcast link available here
February 16: SVB Securities Global Biopharma Conference
- Format: Fireside Chat and 1x1 Meetings
- Webcast link available here
March 7: Cowen 43rd Annual Health Care Conference
- Format: GI/GU Oncology Panel Discussion and 1x1 Meetings
- Time: 12:50pm ET
- Webcast link available here
March 13: Oppenheimer 33rd Annual Healthcare Investor Conference
- Format: Fireside Chat and 1x1 Meetings
March 27: FY2022 Financial Results
April 3: Jefferies Radiopharma Innovation Summit
VIEW 2022 PAST EVENTS
Stock, Financials & Governance
Financial Reports
Board of Directors
Management
Stock Price
SEC Filings
Section 16 Filings
Governance Documents
Audit Committee Charter
Code of Business Conduct and Ethics
Whistleblower Line Information
Compensation Committee Charter
Corporate Governance Guidelines
Nominating and Corporate Governance Committee Charter
Analyst Coverage
Berenberg - Zhiqiang Shu
Brookline - Kemp Dolliver
Guggenheim - Charles Zhu
Jefferies - Suji Jeong
JonesTrading - Justin Walsh
Oppenheimer - Jeff Jones
Piper Sandler - Ted Tenthoff
Raymond James - Rahul Sarugaser
SVB Securities - Faisal Khurshid
TD Cowen - Boris Peaker
Truist - Nicole Germino
William Blair - Andy Hsieh
Please note, this list of analyst coverage may not complete or up to date. Any opinions, estimates or forecasts regarding performance made by analysts do not represent POINT Biopharma or its management team.
Contact
Investor
Relations
1-833-544-2637 x800Please do not submit any private or confidential information using this form. Fields marked with an asterisk (*) are required.
Your submission has been received!